Rosenstock J et al. conducted the PIONEER 3 trial to compare the effectiveness of oral Semaglutide against Sitagliptin in adult Type 2 diabetes patients who were not adequately controlled on Metformin alone or with sulfonylurea. This study robustly evaluated the impacts on HbA1c reduction and the changes in body weight from baseline (1). Study Summary About the Author Ms. Silpa Rani Gajavalli is a postgraduate in pharmaceutical science (M Pharmacy). She has a wealth of acad

Type 2 diabetes mellitus (T2DM) is a major global health challenge, disproportionately affecting low- and middle-income countries. In 2024, 589 million adults aged 20–79 years were living with diabetes, causing 3.4 million deaths and over US$1 trillion in health expenditure; prevalence is projected to reach 853 million by 2050 (1). Beyond hyperglycaemia, T2D is increasingly recognized as a complex, multisystem disorder associated with the cardiovascular, renal, and hepatic sy

Diabetes is a global epidemic affecting around 463 million adults worldwide (1). India is considered the diabetes capital of the world....

Oral Semaglutide was approved by the FDA in September 2019 to improve blood glucose control in adult patients with type 2 diabetes (1). ...